Chronic Myelocytic Leukemia - Genta Obtains Orphan Drug Designation for C-Myb Antisense (LR3001)
Genta Incorporated (Nasdaq: GNTA) announced today that LR3001, an antisense compound directed against a gene known as c-myb, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of chronic myelocytic leukemia (CML). Designation as an Orphan Drug, which is intended to facilitate product development, provides eligibility for a seven-year period of market exclusivity after approval, grants and tax credits for research and development, and reduced filing fees for marketing applications.
(I-Newswire) - Genta obtained rights to LR3001 from Temple University in December 2004. The drug has been tested in two Phase 1 clinical trials in patients with myeloid leukemias. Genta plans to pursue further clinical development of LR3001 in patients with both hematologic cancers and solid tumors.
About LR3001
LR3001 is part of Genta's DNA/RNA Medicines program. This program uses drugs that are based on chemical modifications of DNA or RNA to selectively knock out the function of genes that may be involved in cancer cause or progression. LR3001 targets an oncogene known as c-myb, which is a protein that directly binds to cellular DNA. C-myb is believed to regulate the expression of other genes that are involved in the growth and differentiation of primitive cells, including Bcl-2, Bcl-XL, c-myc, cyclin A1, cyclin D1, cdc2, and Cox-2. Over-expression of c-myb blocks differentiation, promotes proliferation, and decreases apoptosis. Potential clinical targets for LR3001 include CML, malignant melanoma, neuroblastoma, and cancers of the breast, pancreas and colon.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides ( RNA and DNA-based medicines ) and small molecules. Genasense( R ) ( oblimersen sodium ) Injection, the Company's lead compound from its oligonucleotide program is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite( R ) ( gallium nitrate injection ), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: genta.com.
Genta Forward Looking Statement
This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2004.
If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
Immerse yourself in mystery and magic with two exciting new casual games from Focus Multimedia and Big Fish Games Studios, one of the world’s leading casual game developers. Hidden Expedition Titanic and Azada join Focus’ popular Revival range of super-budget price games and are available in a store near you.
Edraw Max enables students, teachers and business professionals to reliably create and publish kinds of diagrams to represent any ideas. With large pre-drawn libraries and more than 4600 vector symbols, drawing couldn't be easier!
New range of cards launched to make you the cover star.Hallmark Cards in partnership with OK Magazine has launched an exclusive and exciting new range of greeting cards that gives people the chance to give family and friends the A-List treatment.
Many people choose not to pursue an accident claim. The reasons range from knowing the insurance company will settle; to they don't want the legal hassles and expense.
Many individuals and businesses have always purchased their personal computers from a well-known provider to pre-conceived specifications. Increasingly...
The effectiveness of SEO and PPC Services are directly related to the quality and quantity of the performance data that they have to work with. If you are seeking assistance in achieving a higher ranking on search engine results, then we suggest you visit RankYourWebsites.com, specialist in this area. If you have found your attempts at optimization to prove fruitless, the representatives at RankYourWebsites.com will have a solution to increase your traffic.
http://www.vineyardsforsalein.com/ - online island vineyard for sale, vineyard for sale paso, texas vineyard for sale, washington vineyard for sale, tuscany vineyard for sale, vineyard for sale santa, vineyard for sale California
Mark Flanagan, Managing Director of Manchester health and safety, food safety and fire safety consultancy, Shieldyourself, discussed the Scores on the Doors scheme when he made a guest appearance on the BBC’s 5 Live Radio Show recently.
